Skip to main content
SpringerLink
Log in

Alemtuzumab/dimethyl fumarate/thiamazole

Graves' disease and lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Popescu V, et al. Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab. Acta Neurologica Belgica 122: 1117-1120, No. 4, 19 May 2022. Available from: URL: http://doi.org/10.1007/s13760-022-01962-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab/dimethyl fumarate/thiamazole. Reactions Weekly 1919, 31 (2022). https://doi.org/10.1007/s40278-022-20973-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-20973-x

Search

Navigation